Stock Price Movement and Market Context
On 4 March 2026, Beryl Drugs Ltd recorded its lowest price in the past year at Rs.15.92, down from its 52-week high of Rs.30. Despite a modest day gain of 0.77%, the stock remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This indicates sustained bearish momentum over multiple time frames. Notably, the stock outperformed its sector by 2.14% today, yet this was insufficient to reverse the broader downtrend.
The broader market environment saw the Sensex open sharply lower by 1,710.03 points but recover by 284.71 points to trade at 78,813.53, still down 1.78% on the day. The Sensex itself is trading below its 50-day moving average, though the 50DMA remains above the 200DMA, signalling mixed technical signals for the market overall. Within this context, Beryl Drugs’ performance has been notably weak.
Financial Performance and Growth Trends
Over the last year, Beryl Drugs has delivered a negative return of -30.92%, significantly underperforming the Sensex’s positive 7.98% return. The company’s long-term growth metrics also reveal subdued momentum. Net sales have grown at an annualised rate of just 10.21% over the past five years, while operating profit has expanded at a modest 5.06% annually. These figures suggest limited expansion in core business operations relative to sector expectations.
Recent quarterly results further underscore the challenges faced. For the nine months ended December 2025, net sales declined by 20.14% to Rs.13.84 crores. The company reported a PBDIT loss of Rs.-0.20 crores and a PBT less other income loss of Rs.-0.61 crores, marking the lowest levels recorded in recent quarters. These figures highlight a contraction in revenue and profitability, contributing to the stock’s downward pressure.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Credit Metrics and Valuation
Beryl Drugs’ ability to service its debt remains constrained, with an average EBIT to interest coverage ratio of 0.75, indicating limited earnings relative to interest obligations. This weak coverage ratio reflects financial strain and raises concerns about the company’s capacity to manage its liabilities effectively.
Despite these challenges, the company’s return on capital employed (ROCE) stands at 11%, which is relatively attractive within its peer group. Additionally, the enterprise value to capital employed ratio is 0.9, suggesting that the stock is trading at a discount compared to historical valuations of its sector counterparts. This valuation metric indicates that the market currently prices in subdued expectations for the company’s future performance.
Long-Term and Recent Performance Comparison
Over the past three years, Beryl Drugs has consistently underperformed the BSE500 index, reflecting persistent difficulties in generating shareholder value. The stock’s negative returns over one year (-30.92%) and three months further reinforce this trend. Profitability has also declined, with profits falling by 7% over the last year, compounding the stock’s challenges.
The majority of the company’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics in the stock.
Considering Beryl Drugs Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Mojo Score and Ratings
Beryl Drugs currently holds a Mojo Score of 31.0, categorised under the ‘Sell’ grade as of 2 September 2025. This represents an upgrade from its previous ‘Strong Sell’ rating, signalling a slight improvement in the company’s overall assessment. The market capitalisation grade stands at 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector.
While the upgrade indicates some positive movement, the overall rating remains cautious, consistent with the company’s recent financial and stock performance.
Summary of Key Metrics
To summarise, Beryl Drugs Ltd’s stock has reached a new 52-week low of Rs.15.92, reflecting ongoing headwinds in revenue growth, profitability, and debt servicing capacity. The stock’s underperformance relative to the Sensex and its sector peers, combined with subdued financial results, has contributed to this decline. Despite a modest valuation appeal based on ROCE and enterprise value metrics, the company’s fundamental challenges continue to weigh on investor sentiment and market pricing.
Investors and market participants will note that the stock’s recent trend reversal after two consecutive days of decline has not yet translated into a sustained recovery, as it remains below all major moving averages. The broader market’s mixed technical signals and the company’s financial profile suggest that the stock’s current valuation reflects cautious market expectations.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
